Media headlines about Chimerix (NASDAQ:CMRX) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chimerix earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.4579623334613 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday, November 10th. ValuEngine lowered Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th.
Chimerix (CMRX) traded up $0.02 during mid-day trading on Monday, hitting $4.92. The stock had a trading volume of 141,000 shares, compared to its average volume of 272,989. Chimerix has a 52-week low of $4.17 and a 52-week high of $6.64. The stock has a market capitalization of $231.87, a PE ratio of -3.44 and a beta of 1.46.
In related news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.40% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Chimerix (CMRX) Share Price” was published by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://baseballnewssource.com/markets/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-chimerix-cmrx-share-price/1818369.html.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.